Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Recipients, adults of the first living or deceased donor kidney transplant;~2. Patients who agreed to participate in the study and signed the informed consent form~Exclusion Criteria:~1. Receptors with a medical history of nephrotic syndrome or focal and segmental glomerulosclerosis confirmed as the etiology of end-stage renal disease;~2. Receptors with poor understanding about chronic kidney disease and its treatment alternatives;~3. Receptors with early history of non compliance to treatment with immunosuppressive drugs;~4. Retransplantation;~5. Multi-organ recipients;~6. Recipients with BMI\> 30 kg / m2;~7. KDPI\> 80%;~8. Cold ischemia time greater than 24 hours;~9. Receptors with a percentage of anti-HLA antibodies above 50%, either class I or Class II;~10. Women of childbearing potential who do not undertake contraceptive methods (condoms or oral contraceptives).~11. Patients receiving immunosuppressive therapy prior to transplantation, except low dose of prednisone;~12. Patients with severe uncontrolled dyslipidemia;~13. Patients who have a known contraindication for administration of any of the immunosuppressive drugs provided for in this study;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- sirolimus +tacrolimus (Type: EXPERIMENTAL): Patients will receive initial dose of 0,05 mg/kg BID oftacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of sirolimus of 3mg once a day to reach blood trough concentration between 4-8 ng/mL.
- everolimus +tacrolimus (Type: EXPERIMENTAL): Patients will receive initial dose of 0,05 mg/kg BID de tacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of 1.5 mg BID of everolimus to reach blood trough concentration between 4-8 ng/mL.
- mycophenolate +tacrolimus (Type: ACTIVE_COMPARATOR): Patients will receive initial dose of 0,1 mg/kg BID de tacrolimusto reach blood trough concentration between Fixed dose of mycophenolate (mycophenolate mofetil, 1 g BID or sodium mycophenolate, 720 mg BID).

Based on this trial design, predict the completion outcome and termination type (if applicable).